Inability of Mitogen-Activated Lymphocytes Obtained from Patients with Malignant Primary Intracranial Tumors to Express High Affinity Interleukin 2 Receptors by Elliott, Lucinda H. et al.
University of Kentucky 
UKnowledge 
Microbiology, Immunology, and Molecular 
Genetics Faculty Publications 
Microbiology, Immunology, and Molecular 
Genetics 
7-1-1990 
Inability of Mitogen-Activated Lymphocytes Obtained from 
Patients with Malignant Primary Intracranial Tumors to Express 
High Affinity Interleukin 2 Receptors 
Lucinda H. Elliott 
University of Kentucky, lucinda.elliott@uky.edu 
W. H. Brooks 
University of Kentucky 
T. L. Roszman 
University of Kentucky 
Follow this and additional works at: https://uknowledge.uky.edu/microbio_facpub 
 Part of the Medical Immunology Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Elliott, Lucinda H.; Brooks, W. H.; and Roszman, T. L., "Inability of Mitogen-Activated Lymphocytes 
Obtained from Patients with Malignant Primary Intracranial Tumors to Express High Affinity Interleukin 2 
Receptors" (1990). Microbiology, Immunology, and Molecular Genetics Faculty Publications. 150. 
https://uknowledge.uky.edu/microbio_facpub/150 
This Article is brought to you for free and open access by the Microbiology, Immunology, and Molecular Genetics at 
UKnowledge. It has been accepted for inclusion in Microbiology, Immunology, and Molecular Genetics Faculty 
Publications by an authorized administrator of UKnowledge. For more information, please contact 
UKnowledge@lsv.uky.edu. 
Inability of Mitogen-Activated Lymphocytes Obtained from Patients with 
Malignant Primary Intracranial Tumors to Express High Affinity Interleukin 2 
Receptors 
Digital Object Identifier (DOI) 
https://doi.org/10.1172/JCI114719 
Notes/Citation Information 
Published in The Journal of Clinical Investigation, v. 86, no. 1. 
© The American Society for Clinical Investigation, Inc. 
The copyright holder has granted the permission for posting the article here. 
This article is available at UKnowledge: https://uknowledge.uky.edu/microbio_facpub/150 
Inability of mitogen-activated lymphocytes obtained from
patients with malignant primary intracranial tumors to express
high affinity interleukin 2 receptors.
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Patients with primary malignant brain tumors manifest a variety of abnormalities in cell-mediated and humoral immunity.
Diminished T cell reactivity has been shown in these patients to be linked to deficiencies in interleukin 2 (IL-2) production
that cannot be overcome by exogenous IL-2. In this study, specific binding of radiolabeled IL-2 to PHA-stimulated
lymphocytes from brain tumor patients demonstrates that the number of high affinity interleukin 2 receptors (IL-2R) is
greatly reduced. FACS analysis indicates that the relative density of the p55 protein (Tac protein) is lower on the mitogen-
activated lymphocytes obtained from patients than on comparably treated lymphocytes from normal individuals. These
data indicate that mitogen-stimulated lymphocytes obtained from patients have fewer functional high affinity IL-2R
principally because of the failure to express sufficient levels of the p55 protein for association with the p75 protein.
Northern analysis of total RNA isolated from mitogen-stimulated T cells from patients demonstrates normal levels of
steady state mRNA, which codes for the p55 protein. Moreover, there is no defect in the postranslational processing of
the primary translation product of this mRNA suggesting that normal levels of the p55 protein are produced in activated T
cells from patients.
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Inability of Mitogen-activated Lymphocytes Obtained
from Patients with Malignant Primary Intracranial Tumors
to Express High Affinity Interleukin 2 Receptors
Lucinda H. Elliott, William H. Brooks, and Thomas L. Roszman
Department of Microbiology and Immunology, University of Kentucky Medical Center, Lexington, Kentucky 40536-0084
Abstract
Patients with primary malignant brain tumors manifest a vari-
ety of abnormalities in cell-mediated and humoral immunity.
Diminished T cell reactivity has been shown in these patients
to be linked to deficiencies in interleukin 2 (IL-2) production
that cannot be overcome by exogenous IL-2. In this study,
specific binding of radiolabeled IL-2 to PHA-stimulated lym-
phocytes from brain tumor patients demonstrates that the
number of high affinity interleukin 2 receptors (IL-2R) is
greatly reduced. FACS analysis indicates that the relative
density of the p55 protein (Tac protein) is lower on the mito-
gen-activated lymphocytes obtained from patients than on
comparably treated lymphocytes from normal individuals.
These data indicate that mitogen-stimulated lymphocytes ob-
tained from patients have fewer functional high affinity IL-2R
principally because of the failure to express sufficient levels of
the p55 protein for association with the p75 protein. Northern
analysis of total RNAisolated from mitogen-stimulated T cells
from patients demonstrates normal levels of steady state
mRNA,which codes for the p55 protein. Moreover, there is no
defect in the postranslational processing of the primary trans-
lation product of this mRNAsuggesting that normal levels of
the p55 protein are produced in activated T cells from patients.
(J. Clin. Invest. 1990. 86:80-86.) Key words: phytohemagglu-
tinin * interleukin 2 * T cells * glioma * Tac protein
Introduction
Patients with primary malignant intracranial neoplasms ex-
hibit broad suppression of immunocompetency as manifest
through a variety of in vivo and in vitro determinants (1-9).
Most notably, the T cell hyporesponsiveness observed in these
patients is a result of the failure of these cells to enter and
complete the proliferative cycle when compared to compara-
bly stimulated T cells obtained from normal individuals (10).
This functional defect of the T cell cannot be attributed to an
inability to bind lectin, enhanced suppressor cell activity (1 1),
or anomalous accessory cell function and secretion of inter-
leukin 1, which are required for stimulation (10). However, T
cells obtained from these patients do not secrete normal
Address reprint requests to Dr. Elliott, Department of Microbiology
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amounts of interleukin 2 (IL-2) after stimulation and the pro-
liferative response cannot be restored by the addition of exoge-
nous IL-2 (12). Collectively, these results suggest that impaired
T cell reactiviness results from an intrinsic defect(s) in lym-
phocytes obtained from patients with malignant gliomas.
Concurrent with secretion of IL-2, appropriately stimu-
lated lymphocytes express distinct classes of receptors for this
lymphokine with differing affinities and apparent function.
Recent studies suggest that the functional high affinity IL-2
receptor (IL-2R)' is composed of at least a 55-kD polypeptide
chain (p55, or Tac protein) and a 75-kD polypeptide chain
(p75) linked by noncovalent interactions (13-18). Although
lymphocyte proliferation can be induced without mitogen via
interaction of IL-2 with p75 (19), the formation of the high
affinity IL-2R is more efficient because the concentration of
IL-2 required to induce proliferation is significantly less in
lymphocytes expressing high affinity IL-2R than in those T
cells expressing the p75 only. As a corollary, failure to assem-
ble and express the high affinity IL-2R would result in dimin-
ished lymphocyte proliferation under physiological condi-
tions. Investigating this possibility as an explanation for di-
minished T cell proliferation observed in patients with
malignant gliomas, we now report that lymphocytes obtained
from these patients express normal levels of the p75. However,
the high affinity IL-2R as well as p55 are significantly lower
than normal after lectin stimulation.
Methods
Patient population. All patients received diagnosis of either glioblas-
toma multiforme or anaplastic astrocytoma with signs of progressive
tumor growth. None received radiation, systemic steroids, or pheny-
toin at the time of the study. Both menand womenranged in age from
18 to 68 yr (median, 42 yr). Healthy hospital employees, ranging in age
from 24 to 56 years (median, 30 yr) served as normal controls.
Lymphocyte preparation and culture. Peripheral blood lympho-
cytes (PBL) were isolated by centrifugation at 400 g for 35 min on a
Ficoll-Hypaque gradient (20). The lymphocyte band was collected,
washed in Hanks' balanced salt solution, and adjusted to 2 X 106
cells/ml in RPMI 1640 medium containing 1%glutamine, nonessen-
tial amino acids, vitamins, sodium pyruvate, antibiotics, 12.5 mM
Hepes, 5 X 10' M2-mercaptoethanol, and 10% fetal bovine serum
(FBS). Aliquots of 20 ml were cultured in 25-cm tissue culture flasks
for 48 h with 50 jsglml PHA-P (Difco Laboratories, Detroit, MI) at
37°C in a moist 5% C02-95% air mixture. The lymphocytes were
harvested at the end of this period and employed in the IL-2R assays as
described below. Purified T cells were isolated by rosette formation
with neuraminidase-treated sheep erythrocytes and centrifugation on a
Ficoll-Hypaque gradient (7).
Radiolabeled IL-2 binding assay. A modification of the method of
Robb et al. (21) was utilized to measure specific binding of '25I-recom-
1. Abbreviations used in this paper: IL-2R, high affinity IL-2 receptor.
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binant IL-2 (specific activity 20-40 gCi/mg; New England Nuclear,
Boston, MA). Briefly, mitogen activated lymphocytes collected at 48 h
after initiation of culture were incubated at 370C in 50 ml of RPMI
1640 for two 1-h periods to remove endogenously bound IL-2. After
extensive washing with 20 ml of RPMI, 3 X 105 cells per tube were
incubated in duplicate for 25 min at 370C with increasing concentra-
tions of '251-recombinant IL-2 (rIL-2). Unlabeled rIL-2 (rIL-2 [ala];
Amgen, Thousand Oaks, CA) was added at 500-1,000-fold excess of
labeled rIL-2 in duplicate tubes to determine nonspecific binding. The
binding reaction was terminated by the addition of 1 ml of ice-cold
binding medium (RPMI 1640 containing 10%FBSand 25 mMHepes)
followed by centrifugation at 13,000 g for 2 min. The cell pellets were
collected and the specific bound '25I-rIL-2 determined in a gamma
counter. The affinity and number of receptor sites per cell was deter-
mined by Scatchard analysis.
Quantitation of IL-2 receptor-positive cells and receptor density. An
indirect immunofluorescence assay was employed to detect lympho-
cytes expressing IL-2 receptors. Lymphocytes were resuspended at a
concentration of 1 X 106 cells in 200 Ml of RPMI 1640 medium con-
taining 10% FBS and 0.02% sodium azide. Five Ml of anti-Tac mono-
clonal antibody (anti-Tac MAb, generously provided by Dr. Thomas
Waldmann, National Institutes of Health) or an irrelevant monoclonal
antibody (G7C10) directed against granulocytes (generously provided
by Dr. John Thompson, University of Kentucky Medical Center) was
added to the cell suspension and the mixture incubated for 30 min on
ice. The cells were washed in PBS pH 7.2 containing 0.02% sodium
azide and 10 Ml of a 1/10 dilution of fluorescein-conjugated (Fab')2
fragments of goat anti-mouse IgG (Cooper Biomedical, Malvern, PA)
added. After incubation on ice for 30 min, the cells were washed in
ice-cold PBScontaining sodium azide, resuspended in 1 ml of PBSand
104 cells analyzed on a Becton-Dickinson FACS-420 (Becton-Dickin-
son, Sunnyvale, CA).
Northern analysis of total RNAfrom activated T cells. Total RNA
was extracted by the method of Chirgwin et al. (22) from both T cells
obtained from normal individuals and patients with gliomas 16-18 h
after stimulation with PHA. The RNAwas electrophoresed on a 1%
agarose gel containing formaldehyde, transferred to nitrocellulose, and
hybridized at 42°C for 48 h with the cDNAclone pI12R2 (generously
provided by Dr. Warner C. Green, Duke University). The pIL2R2
cDNA clone, which corresponds to bases 1-937 of the human p55
IL-2R, was labeled with [a-32P]dCTP by random priming using an
oligonucleotide labeling kit (catalog 27-9250-01; Pharmacia Fine
Chemicals, Piscataway, NJ). The audioradiograms obtained from the
nitrocellulose blots were analyzed using the Visage 2000 Bioimage
Analyzer to determine relative levels of the various p55 mRNAspe-
cies. The blots were stripped and hybridized with a 32p labeled cDNA
probe for ribosomal RNA(rRNA) (generously provided by Dr. Jackie
Featherstone, Louisiana State University Medical Center) to verify
that similar amounts of total RNAwere loaded on the gels.
Pulse-chase labeling. T cells from normal individuals and brain
tumor patients were stimulated with PHAfor 48 h. The cells (1 X 107)
were washed, resuspended in methionine-free RPMI 1640, and pulsed
for 15 min at 37°C with 0.5 mCi of [35S]methionine (translation grade
800 Ci/mmol, Dupont, New England Nuclear Corp., Boston, MA).
Labeling was stopped by centrifugation at 400 g and the cell pellets
were resuspended in complete RPMI containing unlabeled methio-
nine. Culture was continued at 37°C in C02 incubator for 0, 15, 30,60,
120 min, followed by extraction, immunoprecipitation with anti-Tac
MAband analyzed by sodium dodecyl sulfate polyacrylamide gel elec-
trophoresis (SDS-PAGE).
Immunoprecipitation with anti-Tac MAb. The method of Davies
and Brown (23) was used to extract and immunoprecipitate the pre-
cursor and final protein products of the p55 IL-2R gene. Briefly, [35S]-
methionine labeled proteins were extracted from 1 X 107 cells by
incubation on ice for 30 min in 1 ml of lysis buffer (10 mMTris-HCl
buffer, 1% NP-40, 0.5% deoxycholate, 150 mMNaCl, 1 mMEDTA)
containing 1 mg/ml bovine serum albumin (BSA) and 1 mMphenyl-
methylsulfonyl fluoride (PMSF; Sigma Chemical Co., St. Louis, MO).
After centrifugation to remove the nuclei, the lysates were precleared
with washed Staphylococcus aureus (Pansorbin; Calbiochem-Behring,
San Diego, CA) and incubated overnight at 4VC with 10 gg/ml of
anti-Tac MAb. An irrelevant MAb (anti-coronavirus; Chemicon, El
Segundo, CA) of the same class (IgG2a) was added to control tubes.
The lysates were reacted with the antibodies overnight at 4VC, then 50
,Ml of washed Pansorbin was added, and the tubes were incubated at
4VC for 60 min with rotation. The antibody-Pansorbin complexes were
collected by centrifugation at 13,000 g for 5 min and the pellet was
washed successively in 1 ml wash buffer-l (lysis buffer plus 0.5 M
NaCI), wash buffer-2 (lysis buffer plus 0.1% SDS) and wash buffer-3
(10 mMTris-HCl buffer pH 7.4, 0.1% NP-40). The pellets were resus-
pended in 50 Ml of SDSsample buffer (5 mMTris-HCl buffer pH 6.8,
0.4% SDS, 2% glycerol, 1% 2-mercaptoethanol, 0.01% bromophenol
blue) boiled for 5 min and centrifuged 13,000 g for 4 min. The super-
natants were analyzed by electrophoresis on a 10% SDS-polyacryl-
amide gel.
Results
Determination of the number of high affinity IL-2R on PHA-
activated T cells obtainedfrom patients with brain tumors. We
have previously reported that PHA-activated lymphocytes ob-
tained from patients with glioblastomas contain significantly
lower than normal numbers of IL-2 receptor-positive cells, as
measured by indirect immunofluorescent staining with anti-
Tac MAb (12). Since the anti-Tac MAb binds to both the
functional high affinity IL-2R and the nonfunctional low af-
finity p55 IL-2R, it was of interest to determine which of these
receptors was being affected. Binding assays were initiated
using radiolabeled IL-2 to determine the affinity and number
of IL-2R expressed on PHA-activated T cells from patients
with brain tumors. The comparative results of Scatchard anal-
ysis of '251I-I-L2 binding to lymphocytes from a patient with a
brain tumor and a normal subject illustrate that although T
cells obtained from patients express high-affinity IL-2R, the
levels of these receptors are significantly less (threefold) than
those found on lymphocytes obtained from normal individ-
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Figure 1. Typical curves for the binding of 25I-IL-2 and Scatchard
analysis (inset) of high affinity IL-2R expression on PHA-stimulated
lymphocytes obtained from either a patient with a glioblastoma (N)
or a normal subject (-). The lymphocytes were cultured with PHA
for 48 h before performing the binding assay with '251-IL2 as de-
scribed in Methods.
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detectable on mitogen-stimulated T cells collected from four
of seven patients (Table I).
Expression of the p55 and p75 IL-2R on PHA-activated T
lymphocytes obtainedfrom patients with brain tumors. Recent
evidence reveals that the functional high affinity IL-2R is as-
sembled by noncovalent interaction between the p55 IL-2R
and the p75 IL-2R (13-17). The p55 IL-2R binds IL-2 with
low affinity while the p75 IL-2R binds with intermediate af-
finity. Therefore, the possibility exists that an absence of either
the p55 or p75 chains of the IL-2R or failure of their associa-
tion in the assembly of the high-affinity IL-2R could be re-
sponsible for the diminished expression of high-affinity IL-2R
on mitogen-stimulated T cells obtained from brain tumor pa-
tients. Scatchard analysis (Fig. 2) of 125I-IL-2 binding to acti-
vated T cells from a patient illustrates that although these cells
fail to express normal levels of the high affinity IL-2R (591
sites/cell, Kd 8.3 pM) they do express sufficient levels (1,833
sites/cell) of the p75 IL-2R that bind IL-2 with intermediate
affinity (Kd 83 pM). In fact, Scatchard analysis of the data from
binding assays using lymphocytes from three different patients
indicate that the number of p75 IL-2R are present in excess
(greater than threefold) of the high affinity IL-2 binding sites.
Thus, the p75 is readily expressed on activated T cells obtained
from glioma patients and is available for IL-2 binding. How-
ever the relative density of p55, as determined by flow cytome-
try using anti-Tac MAb, is significantly lower on activated T
cells from patients when compared with similarly treated cells
from normal individuals (Fig. 3).
Determination of steady-state levels of mRNAfor p55 in
PHA-stimulated T cells from patients with brain tumors. One
possible explanation for the failure of PHA-activated T cells
from patients to express the p55 might stem from a defect in
the transcription of the gene that codes for this protein.
Northern blot analyses of total RNAextracted from activated







0.0 0.5 1.0 1.5 2.0
Specific bound molecules/cell x 10-3
Figure 2. Typical Scatchard analysis of intermediate and high affinity
IL-2R expression on PHA-stimulated lymphocytes from a patient
with a glioblastoma. See Fig. 1 for details.
II) suggest that although there is variability among both popu-
lations of cells, the T cells obtained from patients and normals
appear to express similar steady state levels of mRNAfor p55.
Moreover, there does not appear to be any significant differ-
ences in the ratio of the two major mRNAspecies (3.5/1.5 kb).
Posttranslational processing of the p55 gene product. Be-
cause there does not appear to be a defect in the transcription
of the gene for p55, it was of interest to determine if the de-
creased expression of this protein on the surface of activated T
cells from patients was the result of a defect in the posttransla-
tional modification of p55. The primary translation product of
the p55 mRNAis a 34-kD peptide (p34) (24). Cleavage of a
signal peptide results in the formation of a 33-kD peptide that
is evident at early time points. Cotranslational addition of
NH2-linked oligosaccharides yields two more precursor pep-
tides p35 and p37. The p35/p37 precursors are further pro-
Table I. Comparison of the Number of High Affinity IL-2R
on Activated T Cells Obtainedfrom Normal Individuals
and Patients with Brain Tumors
IL-2R
sites
Cell source PHAresponse Kd (molecules/cell)
(% of control)* pM
Normal 1 62 3,262
Patient 1 53 NDt 0
Normal 2 14 1,262
Patient 2 33 9 591
Normal 3 22 1,609
Patient3 21 17 466
Normal 4 35 1,602
Patient4 ND 0
Normal 5 62 5,125
Patient 6 30 ND 0
Patient 7 44 ND 0
* Percent of the normal control response of lymphocytes from pa-
tients to 10 Ag/well of PHA.
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Figure 3. Typical immunofluorescent profiles of 48-h PHA-stimu-
lated lymphocytes from a normal individual (A and B) and a patient
with a glioblastoma (C and D) stained with anti-TAC monoclonal
antibody (B and D) and an irrelevant monoclonal antibody (A and
C), as described in Methods.
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cessed in the Golgi through p37 to the mature p55 by the
addition of 0-linked carbohydrates and sialic acid (24).
[35S]Methionine pulse-chase experiments were performed
on PHA-activated T cells from normal individuals and brain
tumor patients to determine if there were any difference in the
posttranslational processing of p55, which might account for
its decreased expression on the cell surface. Radiolabeled pro-
teins were specifically immunoprecipitated with anti-Tac
MAband analyzed by SDS-PAGE(Fig. 5). After 0 and 15 min
Table I. Northern Blot Analysis of Total RNAExtracted
from Activated T Cells from Normal Individuals
and Patients with Brain Tumors
CMll source 3.5 mRNA* 1.5 mRNA 3.5/1.5
Normal 1 0.154 0.373 0.413
Patient 1 0.624 0.492 01.27
Normal 2 0.677 0.535 1.26
Patient 2 0.486 0.337 1.39
Normal 3 0.191 0.080 2.39
Patient3 0.368 0.293 1.25
Normal 4 0.781 0.702 1.11
Patient 4 0.550 0.400 1.38
Patient 5 0.547 0.287 1.64
* The ODvalues for p55 mRNAobtained from Visage 2000 Bio-
image Analyzer were compared to ODvalues obtained for 18s rRNA
and expressed as the ratio of p55 mRNAto 18s rRNA per lane.
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Figure 5. Pulse-chase studies of PHA-activated PBL from normal in-
dividuals (left) and brain tumor patients (right). Precipitations were
done with either anti-Tac or control anti-coronavirus (C-Ab) mono-
clonal antibodies. Time of chase in minutes is on the abscissa and
molecular weight markers on the ordinate. Locations of p35, p37,
and p55 are marked.
of chase with unlabeled methionine, anti-Tac MAbimmuno-
precipitated the p35 and p37 precursor peptides in cell extracts
from normal individuals. Extending the chase period to 30
min results in the movement of label from the p35 precursor to
the p37 precursor. By 60 min label is detected in the mature
p55 and by 120 min all the label is concentrated in the mature
p55. Analysis of immunoprecipitates of cell extracts from
brain tumor patients 0, 60, and 120 min after chase with unla-
beled methionine are presented in lanes 8, 9, and 10 of Fig. 5.
These results are identical to those obtained with PHA-acti-
vated T cells from normal individuals with the appearance of
normal levels of p55 protein by 120 min.
Discussion
The immunologic status of patients with primary malignant
brain tumors is characterized by an impairment of lymphocyte
activation ( 1-9). Previously we have reported the presence of
an intrinsic anomaly in T cells obtained from patients harbor-
ing malignant brain tumors resulting in diminished respon-
siveness and failure to move out of the GI phase of the prolifer-
ative cell cycle (10). Moreover, the T cell hyporesponsiveness
is confined to the T helper cell (CD4) and results, in part, from
the inability of these cells to secrete IL-2 (10). More recently,
we have shown that the addition of IL-2 to PHA-stimulated
PBL from brain tumor patients does not restore their prolifera-
tive levels, to normal values, suggesting a defect in the expres-
sion of the IL-2R (12). Indeed, the number of Tac-positive
cells is less than normal throughout all periods of mitogen
stimulation. The recent findings of the role of high-affinity
IL-2R in providing proliferative signals for lymphocyte trans-
formation raised the question of whether mitogen-stimulated
T cells obtained from these patients were capable of assem-
bling normal levels of high affinity IL-2R. In the present study,
we have utilized the specific binding of radiolabeled IL-2 to
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determine the number and affinity of IL-2R on PHA-activated
T cells obtained from brain tumor patients. The results dem-
onstrate that expression of high affinity IL-2R is suppressed on
these cells when compared to PHA-activated T cells obtained
from normal individuals. Therefore, an attractive explanation
for the impaired lymphocyte reactivity of these patients is the
failure of stimulated T cells to express sufficient levels of the
high affinity IL-2R required for proliferation.
The high affinity IL-2 receptor is a complex structure con-
sisting of at least two noncovalently linked polypeptide chains
(p55 and p75), both of which have binding sites for IL-2
(13-17). Although, recent evidence indicates that the p75
IL-2R is the biologically relevant moiety for transduction of
the IL-2 signal, the induced expression of the p55 after lym-
phocyte stimulation is important in augmenting IL-2 binding
via the newly assembled high affinity IL-2R (19, 25, 26). Nor-
mally, p55 is expressed on activated T cells in excess (10-20
fold) of the p75 (26). It has been hypothesized that one func-
tion of the p55 is to insure that the p75 is always occupied in
the formation of the functional high affinity IL-2R (26). In our
studies, the relative density of the p55 as measured by flow
cytometry using anti-TAC MAb is significantly less on acti-
vated T cells from patients with brain tumors when compared
to similarly treated cells from normal individuals. Moreover,
the intermediate affinity p75 IL-2R is always expressed in ex-
cess (greater than threefold) of the high affinity IL-2R on acti-
vated lymphocytes obtained from patients with brain tumors.
Collectively, these data suggest that mitogen-stimulated T cells
obtained from patients with malignant gliomas express lower
levels of the functional high affinity IL-2R principally because
they have insufficient levels of p55 available for association
with p75.
The explanation for diminished p55 expression after lectin
stimulation remains to be elucidated. It is evident, however,
that altered T cell responsiveness of patients with gliomas is
linked to abnormal IL-2R formation and expression. How-
ever, the earliest events of mitogen-induced lymphocyte acti-
vation required for the development of competency to begin
the proliferative cycle, e.g., lectin binding, phosphoinositide
hydrolysis and protein kinase C translocation, occur normally
in T cells obtained from brain tumor patients (unpublished
observations). It may be hypothesized that the failure to ex-
press p55 and hence inability to assemble high-affinity IL-2R
required for proliferation stems from defects in regulation of
IL-2R gene transcription and/or translation. However, North-
ern blot analysis of total RNAextracted from activated T cells
obtained from patients with brain tumors indicates that these
cells express normal steady-state levels of mRNAfor p55.
Leonard et al. (27) have noted a predominance of the 3.5-kb
species in cells that express low levels of IL-2R. They suggest
that, although both species code for protein, the 1.5-kb species
may be the one that varies with the magnitude of IL-2R ex-
pression. This does not appear to be the case in our system.
The ratio of 3.5/1.5 mRNAis similar for cells obtained from
patients and normal individuals.
The primary translation product of the mRNAfor p55 is a
peptide with a molecular weight of 34 kD (p34), which under-
goes extensive post-translational modification to yield the final
protein product of 55 kD (24). All the precursor peptides ex-
cept p34 bind IL-2, thus, these extensive posttranslation modi-
fications do not appear to be essential to ligand binding. How-
ever, these modifications may alter the affinity with which the
p55 IL-2R binds IL-2 (24). The data presented in this study
with PHA-activated T cells obtained from patients indicate
that mRNAfor p55 is translated into a product which under-
goes normal post-translational processing resulting in synthe-
sis of normal levels of mature p55 protein. Thus, it appears
that the failure of activated T cells from brain tumor patients
to assemble functional high affinity IL-2R can not be attrib-
uted to defects in transcription of the gene or translation of the
mRNAthat code for p55.
These data do not correlate with the observed decreased
expression of the Tac protein on activated T cells from pa-
tients. There are a number of possible explanations that may
account for these discrepancies. First, p55 may be degraded in
lymphocytes from brain tumor patients before it is expressed
on the cell surface. Second, there is evidence (28, 29) that T
cell lines, as well as mitogen-activated lymphocytes from nor-
mal individuals, which express mature p55 on their cell surface
also release measurable levels of this protein into the culture
supernatant. The secreted form demonstrates an apparent mo-
lecular mass of 45-50 kD, which is smaller than the p55 sur-
face receptor on these cells. Thus, the release of soluble p55
IL-2R appears to be a characteristic of T cell activation and
may play an immunoregulatory role in lymphocyte activation
(28). It may be hypothesized that this normal process of p55
IL-2R secretion has been upregulated in activated lympho-
cytes from patients, thus reducing the levels of this protein on
the cell surface. Finally, the glioma may be secreting factors,
which, in some unknown manner mask or prevent the expres-
sion of p55 on the cell surface and prevent assembly of the
functional high affinity IL-2R. Experiments are in progress to
test these possibilities.
The results of the present study provide insights into the
potential therapeutic role of lymphokine-activated killer cells
(LAK-cell), cytotoxic T lymphocytes (CTL) and/or IL-2 infu-
sion, as well as into the immunobiologic relationship between
glioma cells -and lymphocytes. In vitro, high doses of IL-2
promote the growth and expansion of LAK cells obtained
from these patients yet the numbers are greatly reduced when
compared with healthy controls (30-32). Glioma specific CTL
also may be isolated from tumor tissue but are exceedingly low
in their proliferative response to IL-2 (32-34). Moreover,
tumor infiltrating lymphocytes that are positive for a variety of
T cell markers do not express the p55 IL-2R (33). Hence the
inability of lymphocytes obtained from these patients to ex-
press functional high-affinity IL-2R offers one explantation for
the limited inducible expansion of these IL-2-dependent lym-
phocyte subpopulations as well as the relative ineffectiveness
of LAK cells and/or IL-2 in treating patients with malignant
gliomas (35, 36).
The relationship between the presence of a malignant brain
tumor and alterations in intrinsic lymphocyte function as
demonstrated in this and previous investigations remains con-
jectural. Previously, we (37) and others (38-40) have demon-
strated that glioma cells secrete a factor(s) capable of modulat-
ing lymphocyte proliferative responsiveness. These factors
suppress the responsiveness of T cells obtained from both pa-
tients with brain tumors as well as normal individuals. Recent
evidence indicates that glioma suppressor factor(s) impair re-
activity of T cells obtained from healthy individuals by modu-
lation of the expression of the high affinity IL-2R (unpublished
observation); a finding similar to that observed in T cells ob-
tained from patients with gliomas. How this abrogation of
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IL-2R assembly and/or expression is affected is conjectural.
Nonetheless, it is tempting to postulate that broad suppression
of immune responsiveness in glioma patients results from an
interaction between glioma suppressive factor and circulating
T cells, which modifies the ability these cells to express the
functional high affinity IL-2R.
Acknowledgments
Wewould like to thank Dr. Warner C. Greene, Duke Univ., for kindly
providing the cDNA clone pIL2R2 and Dr. Thomas Waldman, Na-
tional Institutes of Health, for the gift of anti-TAC MAb. Wethank
Angie Hardin for preparing this manuscript. Wealso thank Karen
Pollok and Dr. Vincent O'Brien for their critique of this manuscript.
This research was supported by National Institutes of Health grant
CA-18234.
References
1. Brooks, W. H., M. G. Netsky, D. A. Horwitz, and D. E. Nor-
mansell. 1972. Cell-mediated immunity in patients with primary brain
tumors. J. Exp. Med. 136:1631-1747.
2. Brooks, W. H., T. L. Roszman, and A. S. Rogers. 1976. Impair-
ment of rosette-forming T lymphocytes in patients with primary intra-
cranial tumors. Cancer. 37:1869-1973.
3. Brooks, W. H., T. L. Roszman, M. S. Mahaley, and R. Woosley.
1977. Immunobiology of primary intracranial tumors. II. Analysis of
lymphocyte populations in patients with primary brain tumors. Clin.
Exp. Immunol. 29:61-66.
4. Young, H. R., R. Sakala, and A. M. Kaplan. 1986. Inhibition of
cell mediated immunity in patients with brain tumors. Surg. Neurol.
5:19-23.
5. Mahaley, M. S., W. H. Brooks, T. L. Roszman, D. D. Bigner, L.
Duka, and S. Richardson. 1977. Immunobiology of primary intracra-
nial tumors. I. Studies of the cellular and humoral general immune
competence of brain-tumor patients. J. Neurosurg. 46:467-476.
6. Levy, N. L. 1978. Cell-mediated cytotoxicity and serum-me-
diated blocking: evidence that their associated determinants on human
tumor cells are different. J. Immunol. 121:916-922.
7. Roszman, T. L., and W. H. Brooks. 1980. Immunobiology of
primary intracranial tumors. III. Demonstration of a qualitative lym-
phocyte abnormality in patients with primary brain tumors. Clin. Exp.
Immunol. 39:395-402.
8. Braun, 0. P., R. 0. Penn, A. M. Flannery, and J. E. Harris. 1982.
Immunoregulatory cell function in peripheral blood leukocytes of pa-
tients with intracranial gliomas. Neurosurgery. 10:203-209.
9. Wood, G. W., and R. A. Morantz. 1982. In vitro reversal of
depressed T lymphocyte function in the peripheral blood of brain
tumor patients. J. Nail. Cancer Inst. 68:27-33.
10. Elliott, L. H., T. L. Roszman, and W. H. Brooks. 1984. Cyto-
kinetic basis for the impaired activation of lymphocytes from patients
with primary intracranial tumors. J. Immunol. 132:1208-1215.
11. Roszman, T. L., W. H. Brooks, and L. H. Elliott. 1982. Immu-
nobiology of primary intracranial tumors. VI. Suppressor cell function
and lectin-binding lymphocyte subpopulations in patients with cere-
bral tumors. Cancer. 50:1273-1279.
12. Elliott, L., W. Brooks, and T. Roszman. 1982. Role of inter-
leukin-2 (IL-2) and IL-2 receptor expression in the proliferative defect
observed in mitogen-stimulated lymphocytes from patients with brain
gliomas. J. NaWl. Cancer Inst. 78:919-922.
13. Sharon, M. R., R. D. Klausner, B. R. Cullen, R. Chizzonite,
and W. J. Leonard. 1986. Novel interleukin-2 receptor subunit de-
tected by cross-linking under high-affinity conditions. Science (Wash.
DC). 234:859-863.
14. Teshigawara, K., H. M. Wang, K. Kato, and K. A. Smith. 1987.
Interleukin 2 high-affinity receptor expression requires two distinct
binding proteins. J. Exp. Med. 165:223-238.
15. Tsudo, M., R. W. Kozak, C. K. Goldman, and T. A. Wald-
mann. 1986. Demonstration of a non-Tac peptide that binds interleu-
kin 2: A potential participant in a multichain interleukin 2 receptor
complex. Proc. Natl. Acad. Sci. USA. 83:9694-9698.
16. Dukovich, M., Y. Wano, Le Thi Bich Thuy, P. Katz, B. R.
Cullen, J. H. Kehrl, and W. C. Greene. 1987. A second human inter-
leukin-2 binding protein that may be component of high affinity in-
terleukin-2 receptors. Nature (Lond.). 327:518-522.
17. Robb, R. J., C. M. Rusk, J. Yodoi, and W. C. Greene. 1987.
Interleukin 2 binding molecule distinct from the Tac protein: Analysis
of its role in formation of high affinity receptors. Proc. Natl. Acad. Sci.
USA. 84:2002-2176.
18. Saragovi, H., and T. R. Malek. 1987. The murine interleukin-2
receptor Irreversible cross-linking of radiolabeled interleukin-2 to high
affinity interleukin-2 receptors reveals a noncovalently associated sub-
unit. J. Immunol. 139:1918-1926.
19. Bich-Thuy, L. T., M. Dukovich, N. J. Peffer, A. S. Fauci, J. H.
Kehrl, and W. C. Greene. 1987. Direct activation of human resting T
cells by IL-2: The role of an IL-2 receptor distinct from the TAC
protein. J. Immunol. 139:1550-1556.
20. Boyum, A. 1968. Isolation of mononuclear cells and granulo-
cytes from human blood. Isolation of mononuclear cells by one cen-
trifugation and of granulocytes by combining centrifugation and sedi-
mentation at I g. Scand. J. Clin. Invest. 21(Suppl. 97): 110.
21. Robb, R. J., W. C. Greene, and C. M. Rusk. 1984. Low and
high affinity cellular receptors for interleukin 2. J. Exp. Med.
160:1126-1146.
22. Chirgwin, J. M., A. E. Pryubyla, R. J. MacDonald, and W. J.
Rutter. 1979. Isolation of biologically active ribonucleic acid from
sources enriched in ribonuclease. Biochemistry. 18:5294-5299.
23. Davies, A. A., and M. H. Brown. 1987. Biochemical character-
ization of lymphocyte surface antigens. In Lymphocytes: a Practical
Approach. G. G. B. Klaus, editor. IRL Press, Oxford and Washington
DC. 236-238.
24. Leonard, W. J., J. M. Depper, M. Kronke, R. J. Robb, T. A;
Waldman, and W. C. Greene. 1985. The human receptor for T-cell
growth factor. Evidence for variable post-translational processing,
phosphorylation, sulfation, and the ability of precursor forms of the
receptor to bind T-cell growth factor. J. Biol. Chem. 260:1872-1880.
25. Robb, R. J., and W. C. Greene. 1987. Internalization of inter-
leukin 2 is mediated by B chain of the high-affinity interleukin 2
receptor. J. Exp. Med. 165:1201-1206.
26. Smith, K. A. 1988. The interleukin 2 receptor. Adv. Immunol.
42:165-179.
27. Leonard, W. L., M. Kronke, N. J. Peffer, J. M. Depper, and
W. C. Greene. 1985. Interleukin 2 receptor gene expression in normal
human T lymphocytes. Proc. Natl. Acad. Sci. USA82:6281-6285.
28. Rubin, L. A., C. C. Kurman, M. E. Fritz, W. E. Biddison, B.
Boutin, R. Yarchoan, and D. L. Nelson. 1985. Souble interleukin 2
receptors are released from activated human lymphoid cells in vitro. J.
Immunol. 135:3172-3177.
29. Nelson, D. L., L. A. Rubin, C. C. Kurman, M. E. Fritz, and B.
Boutin. 1986. An analysis of the cellular requirements for the produc-
tion of soluble interleukin-2 receptors in vitro. J. Clin. Immunol.
6:114-120.
30. Jacob, S. K., D. J. Wilson, P. L. Kornblith, and E. A. Grimm.
1986. In vitro killing of human glioblastoma by interleukin-2 activated
autologous lymphocytes. J. Neurosurg. 65:114-117.
31. Whiteside, T. L., Y. L. Wang, R. G. Selker, and R. B. Herber-
man. 1988. In vitro generation and antitumor activity of adherant
lymphokine-activated killer cells from the blood of patients with brain
tumors. Cancer Res. 48:6069-6075.
32. Kuppner, M. C., M. F. Hamou, and N. De Tribolet. 1988.
Immunohistological and functional analyses of lymphoid infiltrates in
human glioblastomas. Cancer Res. 48:6926-6932.
33. Miescher, S., T. L. Whiteside, N. De Tribolet, and V. V.
Interleukin 2 Receptor Expression on T Cells from Brain Tumor Patients 85
Fliedner. 1988. In situ characterization, clonogenic potential, and an-
titumor cytolytic activity of T lymphocytes infiltrating human brain
cancers. J. Neurosurg. 68:438-448.
34. Sawamura, Y., H. Abe, T. Aida, M. Hosokawa, and H. Ko-
bayashi. 1988. Isolation and in vitro growth of glioma-infiltrating lym-
phocytes, and an analysis of their surface phenotypes. J. Neurosurg.
69:745-750.
35. Merchant, R. E., A. J. Grant, L. H. Merchant, and H. F. Young.
1988. Adoptive immunotherapy for recurrent glioblastoma multi-
forme using lymphokine activated killer cells and recombinant inter-
leukin-2. Cancer. 62:665-671.
36. Jacobs, S. K., D. J. Wilson, P. L. Kornblith, and E. A. Grimm.
1986. Interleukin-2 and autologous lymphokine-activated killer cells
in the treatment of malignant glioma. J. Neurosurg. 64:743-749.
37. Roszman, T. L., W. H. Brooks, and L. H. Elliott. 1987. Inhibi-
tion of lymphocyte responsiveness by a glial tumor cell-derived sup-
pressive factor. J. Neurosurg. 67:874-879.
38. Fontana, A., H. Hengartner, N. de Tribolet, and E. Weber.
1984. Glioblastoma cells release interleukin 1 and factors inhibiting
interleukin 2-mediated effects. J. Immunol. 132:1837-1844.
39. Rutka, J. T., M. L. Rosenblum, R. Stem, H. J. Ralston, D.
Dougherty, and S. De Armond. 1989. Isolation and partial purification
of growth factors with TGF-like activity from human malignant
gliomas. J. Neurosurg. 71:875-883.
40. Kuppner, M. C., M. F. Hamou, Y. Sawamura, and N. De
Tribolet. 1989. Inhibition of lymphocyte function by glioblastoma
derived transforming growth factor. J. Neurosurg. 71:211-217.
86 L. H. Elliott, WH. Brooks, and T. L. Roszman
